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Synopsis
Although efforts to understand the basis for inter-strain phenotypic variation in the most virulent malaria species,
Plasmodium falciparum, have benefited from advances in genomic technologies, there have to date been few meta-
bolomic studies of this parasite. Using 1H-NMR spectroscopy, we have compared the metabolite profiles of red blood
cells infected with different P. falciparum strains. These included both chloroquine-sensitive and chloroquine-resistant
strains, as well as transfectant lines engineered to express different isoforms of the chloroquine-resistance-conferring
pfcrt (P. falciparum chloroquine resistance transporter). Our analyses revealed strain-specific differences in a range of
metabolites. There was marked variation in the levels of the membrane precursors choline and phosphocholine, with
some strains having >30-fold higher choline levels and >5-fold higher phosphocholine levels than others. Chloroquine-
resistant strains showed elevated levels of a number of amino acids relative to chloroquine-sensitive strains, including
an approximately 2-fold increase in aspartate levels. The elevation in amino acid levels was attributable to mutations
in pfcrt. Pfcrt-linked differences in amino acid abundance were confirmed using alternate extraction and detection
(HPLC) methods. Mutations acquired to withstand chloroquine exposure therefore give rise to significant biochemical
alterations in the parasite.
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INTRODUCTION
Malaria, an ancient disease caused by protozoan Plasmodium
parasites, continues to inflict a devastating toll in many parts of
the world. Plasmodium falciparum, the most virulent of the mal-
aria parasite species infectious to humans, has a demonstrated
ability to evolve in response to pressures exerted by drug treat-
ments and host immune responses. Many strains of P. falciparum
have been isolated from different parts of the world and their
phenotypes (e.g., drug susceptibility profiles, growth rates and
transmissibility) investigated. Work on understanding the mo-
lecular basis for important phenotypic differences is underway
and has benefited from advances in genomic, transcriptomic and
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proteomic technologies [1]. Recent years have seen the first re-
ported ‘metabolomic’ analyses of malaria parasite strains [2–5].
However, to date, no untargeted metabolomic comparisons of
genetically divergent strains have been reported.
One P. falciparum adaptation that represented a significant
setback to malaria control efforts was the acquisition of CQ
(chloroquine) resistance. The synthetic drug CQ was cheap, safe
and unusual in that it remained effective for decades, despite hav-
ing been deployed as a monotherapy on a massive scale. How-
ever, CQR (CQ-resistant) parasites eventually arose in several
locations, and they subsequently disseminated throughout most
malaria-endemic areas [6,7], rendering CQ largely ineffective.
CQ resistance is associated with mutations in PfCRT (P. fal-
ciparum chloroquine resistance transporter) [8], a 424 amino
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acid integral membrane protein. PfCRT localizes to the mem-
brane of the parasite’s internal DV (digestive vacuole) [8,9], an
acidic organelle in which haemoglobin endocytosed from the
host RBC (red blood cell) is catabolized, releasing peptides and
haem. CQ accumulates to high concentrations in this compart-
ment through a combination of weak-base trapping and haem
binding [10], and is believed to kill the parasite by inhibiting
the process by which toxic haem monomers are converted into
inert haemozoin crystals [11]. Expression of wild-type PfCRT
and a mutant form of the protein (from the CQR Dd2 strain) in
Xenopus laevis oocytes revealed that the mutant protein mediates
CQ transport, whereas the wild-type protein does not [12]. This
is consistent with previous biochemical studies that had provided
indirect evidence for mutant PfCRT-mediated CQ efflux from
the DV [13–15], and explains (at least in part) the reduced in-
travacuolar CQ accumulation observed in parasites with mutant
PfCRT [10].
Much remains to be learned about what impact PfCRT muta-
tions have on the parasite, beyond enabling it to withstand higher
CQ concentrations. It is clear that mutations in PfCRT affect the
susceptibility of the parasite to a number of other antimalarial
drugs [16] and to a diverse range of other compounds [17], and
there is indirect evidence for the transport of a range of drugs
and ‘chloroquine resistance reversers’ by mutant forms of the
protein [18,19]. Moreover, a number of these drugs and com-
pounds have been shown to interact with mutant PfCRT in the
Xenopus oocyte system (reviewed in [20]). This suggests that
mutations in PfCRT have broadened the substrate specificity of
the transporter well beyond that required to accommodate CQ.
Furthermore, there are differences in the proteomes [21] and gene
expression levels [22] of CQS (CQ-sensitive) and CQR para-
sites, suggesting that PfCRT mutations may have wide-reaching
impacts on parasite biology. Attempts to disrupt the pfcrt gene
have been unsuccessful [23], consistent with PfCRT performing
a function that is essential for parasite survival. It remains unclear
what this function is, or what the natural substrate(s) of PfCRT
might be.
In this study, we have used a combination of 1H-NMR and
HPLC analyses to compare metabolite profiles of uRBCs (un-
infected RBCs) and RBCs infected with different strains of P.
falciparum. The analyses included parasites expressing different
isoforms of PfCRT, allowing us to gain insight into the biochem-
ical consequences of mutations in this transporter.
EXPERIMENTAL
Cells and techniques
Seven strains of P. falciparum were examined in this study. 3D7
(isolated in the Netherlands but possibly of African origin [24])
and D10 (from Papua New Guinea) are laboratory-adapted CQS
strains, while 7G8 (from Brazil) and K1 (from Thailand) are
laboratory-adapted CQR strains. C2GC03, C4Dd2 and C67G8 (a gift
from Professor David Fidock) are transfectant lines generated us-
ing GC03 [16], a CQS progeny of the HB3×Dd2 cross [25]. The
C4Dd2 and C67G8 lines were generated by replacing the wild-type
pfcrt allele in GC03 with the CQ resistance-conferring mutant
alleles of pfcrt from the Dd2 strain (of Thai origin) and the 7G8
strain, respectively. C67G8 contains an additional I351 M muta-
tion in PfCRT that does not occur in 7G8 parasites [18]. The
C2GC03 line is a CQS recombinant control line that expresses the
wild-type pfcrt coding sequence.
The use of human blood in this study was approved by the
Australian National University’s Human Research Ethics Com-
mittee.
Parasites were cultured as described previously [26], and
synchronized by sorbitol treatment [27]. The ‘parasite cul-
ture medium’ consisted of RPMI supplemented with HEPES
(25 mM), additional glucose (10 mM, giving a final concentra-
tion of 20 mM), gentamicin sulfate (24 mg l− 1), hypoxanthine
(0.2 mM) and Albumax II (0.6 % w/v). The pfcrt transfectant lines
were maintained in the presence of the selection agents blasti-
cidin (5 μM; Life Technologies) and WR99210 (5 nM; Jacobus
Pharmaceuticals). Experiments were conducted on mature intact
trophozoite-iRBCs (infected RBCs).
iRBCs were separated from the uninfected cells present in the
cultures [henceforth referred to as cRBCs (‘co-cultured’ RBCs)]
using a magnet (either a VarioMACS Separator with a CS column
or a SuperMACS II Separator with a D column; Miltenyi Biotec),
essentially as described previously [5]. Briefly, the cells were
centrifuged and resuspended in PBS (pH 7.4) supplemented with
0.5 % (w/v) Albumax II and 20 mM glucose immediately before
being passed through a column placed within the separation unit’s
magnetic field. The iRBCs were retained on the column whereas
the cRBCs flowed through. After the cRBCs were eluted (with
the solution described above), the iRBCs (>95 % parasitaemia
for NMR analysis; 92 % for HPLC analysis) were recovered
from the column. For experiments on cRBCs, ∼3 ml of eluate
was collected from the column, while it was in the magnetic
field. There was <5 % contamination of this predominantly cRBC
suspension with iRBCs. For experiments on uRBCs that had
been cultured (for ∼48 h at 37 ◦C in parasite culture medium) in
separate flasks not containing iRBCs (henceforth referred to as
uRBCs), the cells were also passed through the column placed
within the magnetic field and the eluate collected.
After passing through the column the cells (iRBCs, cRBCs or
uRBCs) were, in all cases, resuspended (typically at a density
of 1–4×108 cells/50 ml) in parasite culture medium, and were
allowed to recover at 37 ◦C, typically for 1 h, but in some cases
for up to 4 h. HPLC experiments using iRBCs sampled 1, 2, 3
and 5.5 h post-magnet-enrichment revealed that amino acid levels
remained approximately constant throughout this time period
(results not shown). This suggests that a 1 h recovery time was
adequate and, furthermore, that minor differences in the average
age of the trophozoite–iRBC population between experiments
would not give rise to significant variation in the metabolite levels.
At the end of the recovery period, the cell suspensions (in 50 ml
tubes) were cooled to 4 ◦C within 80 s in a dry-ice/ethanol bath,
and then centrifuged (700×g, 3 min) at 4 ◦C to sediment the cells.
The supernatant solutions were aspirated, and the pellets were
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resuspended in ice-cold PBS (not supplemented with glucose or
Albumax II; ∼50 ml) before being centrifuged again as above.
The washed cells were then resuspended in a known volume
(1–2 ml) of ice-cold PBS and a sample (10 μl) was taken for
cell counting (using an improved Neubauer counting chamber)
before pelleting the cells by centrifugation (5000×g, 1 min) at
4 ◦C. The supernatant solutions were removed, and the pellets
frozen immediately by transferring to liquid nitrogen. The frozen
pellets were stored at − 80 ◦C prior to extraction.
Extraction of metabolites
For the 1H-NMR studies, the metabolites were extracted using
HClO4, which has previously been shown to have advantages over
other extraction media [5]. Ice-cold HClO4 (5 % w/v; 800 μl) was
added to each of the frozen pellets and the samples were trans-
ferred to an ultrasonic bath for 20 min, with mixing (30 s using a
vortex) at 5 and 15 min. At the end of the 20 min the samples were
centrifuged (20800×g, 10 min) and the supernatant solutions
were collected and approximately neutralized by the addition
of 10 M KOH. The samples were then centrifuged at 20800×g
for 10 min to remove the precipitated KClO4. The supernatant
solutions were adjusted to approximately pH 7.0 by addition of
1 M HCl or KOH, centrifuged again to remove the precipitate
(when necessary) then freeze dried and stored at − 20 ◦C until
analysis.
For HPLC (performed primarily to analyse amino acid levels
in iRBCs), methanol was used for extraction. It has been shown
previously that methanol and HClO4 extract most amino acids
with comparable efficiency [5]. First, the non-naturally occurring
amino acid benzylserine (dissolved in methanol) was added to the
pellets as a reference compound, in an amount proportional to
the number of iRBCs in the sample (3.26 mmol per 107 iRBCs).
HPLC-grade methanol (300 μl) was then added. The samples
were mixed by vortexing, and then incubated at 70 ◦C for 20–
25 min, with vortexing every ∼5 min. They were then centrifuged
(13300×g, 10 min) and the supernatant solutions were filtered
into HPLC vials. The methanol was evaporated using a Genevac
miVac Duo concentrator (∼100 min) and the samples stored at
− 20 ◦C prior to derivatization.
NMR analysis
The freeze-dried extracts were dissolved in a known volume of
D2O (500–600 μl) buffered at pH 7.0 with 100 mM phosphate,
with TSP (trimethylsilyl-2,2,3,3-tetradeuteropropionic acid) ad-
ded at a concentration of 0.145 mM. TSP was used both as an
internal chemical shift reference (0 ppm) and as an intensity
reference. The pH of the dissolved NMR samples was further
adjusted to neutral when necessary, using small volumes of DCl
or NaOD (<5 μl). The samples were centrifuged for 5 min at
16100×g to remove any insoluble material, and 490–550 μl of
the supernatant solutions were transferred to Wilmad NMR tubes
(5 mm OD) for 1H-NMR analysis.
The 1H-NMR spectra were acquired and processed essentially
as described previously [5], with 16–128 free induction decays
collected over a spectral width of 12 ppm and an acquisition time
of 4 s, with a 1 s relaxation delay. Concentrations of metabol-
ites in the NMR samples were estimated by importing the spectra
into the Chenomx NMR suite (4.6 or 5.0) [28]. This software uses
the known concentration of a reference compound (TSP in this
study) to determine the concentrations of other compounds. The
Chenomx NMR program, to which a number of compounds had
been added previously [5] and to which 2,3-bisphosphoglycerate
(5 mM with TSP at 1 mM) was added for the purpose of this
study, was able to fit almost all of the peaks in the spectra. The
identity of sorbitol was confirmed by addition of an authenticated
standard. The peak assignments for myoinositol and acetate were
confirmed in 2D NMR [HSQC (heteronuclear single-quantum
coherence)] analyses of parasite extracts, as described in our pre-
vious study [5]. The peak assignments for sarcosine and formate
were reliant on a limited number of spectral signals and should
be regarded as tentative. The signal-to-noise ratios of the low-
est intensity signals from which metabolite concentrations were
estimated were typically>6 (Supplementary Figure S1).
HPLC analysis
The freeze-dried extracts were dissolved in 95 μl of 100 mM
sodium bicarbonate (in water, pH 9) and sonicated for 30 s to
ensure complete solubilization of the pellets. A 5-μl aliquot of
10 mM TNBS (2,4,6-trinitrobenzenesulfonic acid, used to deriv-
atize, and thus allow HPLC-detection of compounds containing
amino groups [29]) in methanol was added and the samples were
then incubated for 2 h at 37 ◦C.
The derivatized samples were analysed using a Dionex Ulti-
mate 3000 RSLC system. The analytes were separated on a Grace
Vision HT C18 HL column (1.5 μm, 2.0×100 mm) at 35 ◦C, us-
ing a flow rate of 0.5 ml/min with 100 mM ammonium acetate
in water, pH 7 (A), and acetonitrile (B) as the mobile phase. The
mobile phase gradient was set up as follows: 0 min: 90 % A and
10 % B, 10 min: 50 % A and 50 % B, 12–14 min: 100 % B, 15–
20 min: 90 % A and 10 % B. The derivatized compounds were
detected at 335 nm using a Dionex Diode Array Detector.
Measurements of radiolabelled aspartate and CQ
uptake in X. laevis oocytes expressing PfCRT or rat
GLAST (glutamate–aspartate transporter)
In vitro transcription, oocyte preparation and microinjection
of PfCRT cRNA (20 ng per oocyte) and GLAST cRNA (5 ng
per oocyte) were performed as described elsewhere [12,30].
GLAST cRNA was a gift from Professor Stefan Bröer [31].
[3H]CQ (0.25 μM; 20 Ci/mmol) and [14C]L-aspartate (6.4 μM;
217 mCi/mmol) uptake by oocytes was measured (3–5 days post-
injection) as described previously [30] over 2 h at 27.5 ◦C, and
in a medium that, unless specified otherwise, contained 96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM MES
and 10 mM Tris-base (pH 5.5). [3H]CQ uptake was measured in
the presence of 15 μM unlabelled CQ.
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RESULTS
1H-NMR estimates of metabolite amounts in uRBCs
and P. falciparum-iRBCs
In initial experiments, the metabolite profile of iRBCs (infected
with 3D7 parasites) was compared with that of cRBCs cultured
in the same flask, as well as with that of uRBCs (from the same
batch) cultured concurrently in a separate flask. Six independent
experiments were performed with O + blood from four different
donors, with the blood having been stored at 4 ◦C for 6–23 days
prior to use.
Representative 1H-NMR spectra of HClO4 extracts derived
from iRBCs, cRBCs and uRBCs are shown in Figure 1. Overall,
more than 40 metabolites were identified in the 1H-NMR ana-
lysis. These included amino acids, GSSG, nucleotides, soluble
phospholipid precursors, carboxylates, polyamines and HEPES
(Table 1). GSH was not detected, consistent with it having been
oxidized to GSSG during the preparation of samples for NMR
analysis, as noted previously [5]. Glucose was not detected in the
3D7 iRBCs and the amount detected in uRBCs and cRBCs was
highly variable. Low levels of glucose were detected in some, but
not all, of the extracts obtained from RBCs infected with other
parasite strains (see Table 3); again, the amounts detected were
highly variable. The absence of glucose from most, although
not all, samples, and the high degree of variability seen, is most
likely due to the rapid loss of glucose during sample prepar-
ation. Glucose is unusually susceptible to loss during sample
preparation because: (i) it traverses the parasite and erythro-
cyte plasma membranes extremely rapidly (on a timescale of
a few seconds under physiological conditions [5,32]); and (ii)
in the case of iRBCs, it is consumed by the parasite’s primary
means of energy generation, glycolysis, at a very high rate.
Although the cells were cooled to 4 ◦C before processing, and
this will have slowed both transport and metabolism, there will
have been residual levels of both activities operating throughout
the sample preparation procedure, leading to the loss of
glucose.
Table 1 Metabolite amounts in uRBCs, cRBCs and RBCs infected with 3D7 trophozoites (iRBCs)
The metabolite amounts (μmol per 1012 cells; obtained by 1H-NMR) are the means (shown +− S.D.) from 6 independent cell preparations
(obtained on different days). The cRBC preparations contained up to 5 % contamination with iRBCs and the iRBC preparations had up to 5 %
contamination with cRBCs. Depending on the metabolite, the amounts presented here are all within 95%-109 % of the values that would have
been obtained had the cell preparations been 100 % pure. nd, not detected in some or all replicates. aP < 0.001, bP < 0.01 and cP < 0.05,
compared to uRBC, from one-way ANOVA tests using the natural logarithm transformed data (nd data excluded). The P values were corrected
for multiple hypothesis testing using the False Discovery Rate (FDR) method of Benjamini and Hochberg [51]. Red shading: more abundant in
iRBCs than in uRBCs; green shading: less abundant in iRBCs than in uRBCs.
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Table 1 Continued
Calculation of the ‘energy charge ratio’ [(ATP + 0.5
ADP)/(ATP + ADP + AMP)] using the averaged data from
Table 1 yielded values of 0.92, 0.89 and 0.87 for uRBCs, cRBCs
and iRBCs, respectively. These all fall within the normal range
(0.85–0.95) for cells dependent on glycolysis [33], consistent
with the cells having been in good condition prior to extraction.
The metabolite profiles of uRBCs and cRBCs were similar to
one another, but quite different from the metabolite profile of iR-
BCs (Figure 1 and Table 1). In particular, the γ -amino acid GABA
(4-aminobutyrate), the phospholipid precursors phosphocholine
and phosphoethanolamine, the TCA (tricarboxylic acid) cycle
intermediates fumarate, α-ketoglutarate, malate and succinate,
and the polyamines putrescine, spermidine and spermine, were
all undetectable by 1H-NMR in uRBCs but present in iRBCs.
Conversely, betaine, creatine, hypoxanthine, ornithine, sarcosine
and sorbitol were detected by 1H-NMR in uRBCs and cRBCs
but not in iRBCs (note however that ornithine was detectable in
iRBCs by HPLC; below).
Some compounds were present in all three cell types, but
were significantly more abundant in iRBCs than in either of the
uRBC populations (Table 1). HEPES (the most abundant solute in
iRBCs) was one such compound, consistent with this exogenous
buffering agent (used widely for the in vitro culture of malaria
parasites) being taken up by the parasite, as shown previously
in a study of D10 parasites isolated from their host RBCs [5].
Other compounds significantly more abundant in iRBCs than in
uRBCs or cRBCs included the amino acids glutamate, histidine,
lysine and threonine, as well as choline, NAD+ and NADP+
and acetate. Alanine and lactate were elevated in both iRBCs and
cRBCs relative to uRBCs. Conversely, isoleucine and leucine
were less abundant in iRBCs than in uRBCs and cRBCs. 2,3-
Bisphosphoglycerate was significantly less abundant in cRBCs
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Figure 1 Representative 1H-NMR spectra of HClO4 extracts of iRBCs (top), cRBCs (middle) and uRBCs (bottom)
1. Leucine, 2. Isoleucine, 3. Valine, 4. Lactate, 5. Threonine, 6. Alanine, 7. Putrescine, 8. Spermidine, 9. Spermine, 10.
Acetate, 11. Glutamate, 12. Oxidized glutathione, 13. 4-Aminobutyrate, 14. Pyruvate, 15. Succinate, 16. α-Ketoglutarate,
17. Glutamine, 18. Malate, 19. Aspartate, 20. Sarcosine, 21. Asparagine, 22. HEPES, 23. Lysine, 24. Creatine, 25.
Ornithine, 26. Choline, 27. Phosphocholine, 28. Carnitine, 29. Arginine, 30. Betaine, 31. myo-Inositol, 32. Glycine, 33.
Sorbitol, 34. Serine, 35. Phosphoethanolamine, 36. 2,3-Bisphosphoglycerate, 37. NAD+ , 38. ATP, 39. Glucose. Other
metabolites listed in Table 1 are not in the region shown. The horizontal bar in the top panel signifies that the peak was
truncated.
than in uRBCs, and was less abundant still in iRBCs, consistent
with a previous study [34].
1H-NMR estimates of metabolite amounts in RBCs
infected with different P. falciparum strains
Using 1H-NMR the intracellular amounts of 39 metabolites were
estimated for a number of different CQS and CQR strains de-
rived originally from field isolates (the CQS strains 3D7 and D10
and the CQR strains 7G8 and K1). The results are presented in
Table 2. The ANOVA test identified a range of metabolites for
which levels showed significant differences among these genet-
ically divergent strains (Table 2). Choline and phosphocholine in
particular showed marked variation between strains, being >30-
fold and >5-fold more abundant, respectively, in 3D7 (CQS)
and 7G8 (CQR) iRBCs than in D10 (CQS) and K1 (CQR) iRBCs
(Table 2). These differences, as well as many others, did not track
with the CQ resistance status of the strain, and presumably result
from genetic differences other than those in pfcrt. We did how-
ever observe that a number of different amino acids, as well as
the total pool of amino acids, were elevated in both CQR strains
compared with both CQS strains.
We also estimated metabolite amounts for three transfectant
lines that differ solely with respect to the isoform of PfCRT that
they express (the CQS line C2GC03 and the CQR lines C4Dd2 and
C67G8; Table 3). The ANOVA test identified a number of meta-
bolites for which levels showed significant differences between
lines (Table 3). We again observed that many individual amino
acids, as well as the total pool of amino acids, were elevated
in both CQR lines relative to the CQS line. Across Tables 2
and 3, RBCs infected with all the four (transfectant and non-
transfectant) CQR strains showed higher amounts of aspart-
ate, asparagine, glycine, leucine and serine than those infected
with any of the three CQS strains. The amount of the polyam-
ine spermine was also greater for CQR strains than for CQS
strains.
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Table 2 Metabolite amounts in RBCs infected with different (non-transfectant) P. falciparum strains
The amounts (μmol per 1012 cells; obtained by 1H-NMR) are the means +− S.D. from the indicated number of independent cell preparations
(obtained on different days). In all cases, the cells were mature trophozoite-infected RBCs. The amounts shown are derived from cell preparations
with up to 5 % contamination with cRBCs. nd, not detected in some or all replicates. a: P < 0.001; b: P < 0.01 and c: P < 0.05 from FDR-adjusted
one-way ANOVA tests using the natural logarithm transformed data (see Table 1; nd data excluded). Metabolites for which there were significant
differences in abundance among strains are shown in bold.
ANOVA 3D7 D10 7G8 K1
No. of independent cultures 10 9 10 8
CQ resistance status CQS CQS CQR CQR
Amino acids
Alanine a 7.8 +− 1.7 11.5 +− 1.8 20.4 +− 4.7 13.9 +− 3.2
4-Aminobutyrate a 4.3 +− 2.5 34.9 +− 8.9 23.2 +− 9.3 26.0 +− 7.2
Arginine a 33.2 +− 16.1 69 +− 21 50 +− 9 76 +− 18
Asparagine a 29.0 +− 7.7 30.0 +− 4.7 42 +− 8 35.9 +− 6.1
Aspartate a 54 +− 12 50 +− 10 117 +− 21 185 +− 54
Glutamate a 166 +− 18 237 +− 26 245 +− 37 238 +− 46
Glutamine c 58 +− 9 54 +− 11 50 +− 9 44 +− 8
Glycine a 8.8 +− 3.2 11.3 +− 1.7 21.7 +− 5.1 12.9 +− 2.2
Histidine a 8.9 +− 3.3 9.6 +− 3.3 20.3 +− 5.1 13.7 +− 2.8
Isoleucine c 5.9 +− 1.4 5.6 +− 1.6 8.4 +− 1.6 6.3 +− 1.9
Leucine a 9.7 +− 2.9 11.1 +− 2.4 17.8 +− 3.6 11.4 +− 3.2
Lysine a 48 +− 22 96 +− 20 77 +− 13 239 +− 64
Phenylalanine c 2.3 +− 3.2 4.4 +− 4.3 3.7 +− 3.4 9.0 +− 14.9
Serine a 15.3 +− 4.0 12.6 +− 2.5 27.3 +− 7.6 18.2 +− 3.7
Threonine b 15.7 +− 3.6 18.3 +− 2.4 21.8 +− 3.9 16.8 +− 3.0
Tyrosine a 4.4 +− 2.0 4.4 +− 1.5 6.8 +− 1.3 4.1 +− 0.8
Valine a 7.9 +− 1.7 9.3 +− 1.0 11.8 +− 2.2 8.1 +− 1.0
Total amino acids a 479 +− 92 669 +− 63 763 +− 99 960 +− 126
Glutathione
GSSG c 43 +− 10 54 +− 10 48 +− 7 54 +− 9
Soluble membrane precursors
2,3-Bisphosphoglycerate b 114 +− 29 81 +− 25 110 +− 21 132 +− 18
Choline a 33.2 +− 11.5 nd 52 +− 9 1.2 +− 0.8
myo-Inositol b 5.4 +− 1.5 7.8 +− 1.4 7.2 +− 1.6 8.1 +− 1.8
Phosphocholine a 220 +− 51 36.7 +− 15.5 223 +− 41 36.2 +− 14.5
Phosphoethanolamine a 38.7 +− 11.3 89 +− 29 82 +− 21 60 +− 20
Nucleotides and related compounds
ADP 14.3 +− 3.1 28.3 +− 12.7 17.9 +− 5.7 19.2 +− 7.7
AMP nd 4.2 +− 3.5 nd nd
ATP b 88 +− 16 124 +− 46 121 +− 20 137 +− 17
NAD+ 56 +− 9 64 +− 9 60 +− 10 54 +− 5
NADP+ c 9.9 +− 1.8 8.7 +− 1.6 7.8 +− 1.2 8.5 +− 1.0
Carboxylates
Acetate 10 +− 6 15 +− 19 10.5 +− 4.3 15 +− 12
Formate 9.9 +− 5.8 14 +− 24 11.5 +− 5.4 15.4 +− 8.4
Fumarate a 0.8 +− 0.6 2.6 +− 0.3 1.5 +− 0.4 1.0 +− 0.6
α-Ketoglutarate 2.5 +− 1.8 2.6 +− 1.3 3.4 +− 0.6 2.8 +− 1.3
Lactate 31.0 +− 7.6 30 +− 14 40 +− 11 50 +− 34
Malate a 13.8 +− 6.5 33.6 +− 7.4 20.4 +− 3.4 15.4 +− 7.1
Succinate a 8.5 +− 1.5 14.6 +− 2.4 9.1 +− 2.6 4.9 +− 2.7
Other compounds
HEPES 540 +− 88 590 +− 80 632 +− 92 544 +− 85
Putrescine a 26.1 +− 8.6 51 +− 15 30.9 +− 6.2 31.2 +− 9.9
Spermidine 164 +− 22 180 +− 26 165 +− 22 167 +− 19
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
691
R. Teng and others
Table 2 Continued
ANOVA 3D7 D10 7G8 K1
Spermine a 8.4 +− 2.2 12.5 +− 2.0 16.1 +− 2.6 16.6 +− 2.4
Total amounts a 1991 +− 170 2210 +− 234 2532 +− 242 2425 +− 194
Total amounts excluding HEPES a 1450 +− 150 1620 +− 172 1900 +− 190 1881 +− 190
Figure 2 shows the ratios of the mean amounts for each (de-
tectable) amino acid in CQR versus CQS strains. In the case of
aspartate, the level seen in all CQR strains was >1.8-fold higher
than that seen in all CQS strains, with the actual amounts differ-
ing by 48 μmol per 1012 cells in all cases. For the other amino
acids that were consistently higher in the CQR strains than the
CQS strains the actual amounts were much lower. These differ-
ences in amino acid abundance were observed both in genetically
disparate CQS (3D7 and D10) and CQR (7G8 and K1) strains
derived originally from field isolates (Table 2, Figure 2), and in
the transfectant lines that differ solely with respect to the form of
pfcrt expressed (Table 3 and Figure 2). The results obtained with
the transfectant lines allow the differences to be attributed to the
differences in pfcrt.
HPLC measurements of metabolites in RBCs
infected with different P. falciparum strains
The finding that mutations in pfcrt give rise to significant dif-
ferences in amino acid abundance was confirmed using HPLC.
The amino acid profiles of the transfectant CQS C2GC03 and
CQR C67G8 lines were compared using the methanol extraction
method, with the extracts subjected to a derivatization proced-
ure to facilitate the detection of compounds containing amino
groups. The HPLC-based approach enabled the detection of 18
amino acids and two polyamines. The absolute amounts of these
metabolites were not quantified; rather, in each experiment, the
metabolite amounts were normalized to that of the non-naturally
occurring amino acid benzylserine (added to each sample as a
reference compound), allowing the determination of the relat-
ive amounts of each amino acid in the two lines. Representative
HPLC traces for each line are shown in Figure 3, and the aver-
aged data from three independent cell preparations are presented
in Table 4.
The data obtained with HPLC were, in general, consistent with
those obtained with 1H-NMR. Of the 20 metabolites detected
by HPLC, two (asparagine and spermine) were only detected
for C67G8. This is consistent with the 1H-NMR data (Table 3),
which revealed greater amounts of asparagine and spermine for
C67G8 than for C2GC03. For each of 13 compounds (12 amino
acids + spermidine), the ratio of the amount in the C67G8 iRBCs
relative to the amount in C2GC03 iRBCs was obtained using both
HPLC and 1H-NMR. The two methods gave good agreement
for the following compounds (although statistical significance
was not reached with HPLC in all cases): alanine, aspartate,
glutamine, glycine, isoleucine, serine, threonine and valine, all of
which were more abundant in C67G8 iRBCs than in C2GC03 iRBCs;
glutamate and spermidine, both of which were more abundant in
C2GC03 iRBCs than in C67G8 iRBCs; and GABA and lysine, levels
of which did not differ significantly between the two parasite
lines. The HPLC measurements indicated a relatively high level
of phenylalanine in C67G8 iRBCs compared to C2GC03 iRBCs;
however, this difference was not statistically significant as there
was a high level of inter-experimental variation, most likely as a
consequence of the low levels of phenylalanine present in both
lines. The 1H-NMR measurements also indicated no significant
difference between phenylalanine levels in C67G8 and C2GC03
iRBCs (Table 3).
HPLC enabled the detection of several metabolites that were
not detected by 1H-NMR. Citrulline and methionine were not
quantified, because they were not detected in all experiments.
Tryptophan was present at twice the amount in C67G8 than in
C2GC03 iRBCs. The amounts of ornithine and the dimeric amino
acid cystine did not differ significantly between C67G8 and C2GC03
iRBCs.
Expression of PfCRT in Xenopus oocytes
One possible explanation for the higher abundance of amino
acids in RBCs infected with CQR parasites is that PfCRT nor-
mally serves to efflux haemoglobin-derived amino acids from
the DV, and that this function is compromised by CQ-resistance-
conferring mutations. Using the Xenopus oocyte expression sys-
tem, we tested whether aspartate, the amino acid showing the
greatest difference in abundance between CQS and CQR strains,
is a substrate of the wild-type (PfCRTCQS) or mutant (PfCRTCQR)
protein. As shown in Figure 4(a), oocytes expressing PfCRTCQS
or PfCRTCQR did not accumulate [14C]L-aspartate above the
levels measured in non-injected oocytes (P>0.05; ANOVA with
Tukey–Kramer multiple comparisons test), whereas oocytes ex-
pressing the rat glutamate/aspartate transporter GLAST showed
a marked increase in [14C]L-aspartate uptake relative to non-
injected oocytes (P<0.001). There was no significant difference
in [14C]L-aspartate uptake between PfCRTCQS- and PfCRTCQR-
expressing oocytes (P > 0.05). Furthermore, [14C]L-aspartate up-
take into PfCRTCQR and PfCRTCQS-expressing oocytes was not
affected by the presence of the PfCRTCQR inhibitors saquinavir
(250 μM; [35]), verapamil (250 μM) or CQ (750 μM) [12], or
by choline (250 μM), artemisinin (500 μM), or unlabelled L-
aspartate (200 μM) (results not shown). In the same experiments,
the transport of [3H]CQ into oocytes expressing PfCRTCQR was
significantly higher than that measured in all other oocyte types
(Figure 4b; P<0.001).
To investigate further whether there might be an interaction
between L-aspartate and PfCRT, we examined whether unla-
belled L-aspartate affected the uptake of [3H]CQ into Xenopus
oocytes expressing PfCRT. As shown in Figure 4(c), the addi-
tion of 1 mM unlabelled L-aspartate had no significant effect on
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Table 3 Metabolite amounts in RBCs infected with mature trophozoite-stage pfcrt transfectant parasites
The amounts (μmol per 1012 cells; obtained with 1H-NMR) are from the indicated number of independent cell preparations (obtained on different
days), and are shown as means +− S.D. The amounts shown are derived from cell preparations with up to 5 % contamination with cRBCs. a:
P < 0.001; b: P < 0.01 and c: P < 0.05 from FDR-adjusted one-way ANOVA tests using the natural logarithm transformed data (see Table 1).
Metabolites for which there were significant differences in abundance among lines are shown in bold.
ANOVA C2GC03 C4Dd2 C67G8
No.of independent cultures 9 8 7
CQ resistance status CQS CQR CQR
Amino acids
Alanine b 15.2 +− 4.5 20.8 +− 6.6 26.7 +− 3.4
4-Aminobutyrate 4.7 +− 2.7 4.8 +− 1.4 3.6 +− 1.1
Arginine c 24.8 +− 7.5 27.9 +− 6.7 16.8 +− 6.6
Asparagine a 22.6 +− 4.5 39.0 +− 8.8 42 +− 9
Aspartate a 54 +− 5 105 +− 30 102 +− 26
Glutamate b 163 +− 26 148 +− 34 105 +− 24
Glutamine a 44 +− 10 66 +− 10 79 +− 21
Glycine a 12.8 +− 2.5 24.1 +− 5.8 27.2 +− 1.5
Histidine b 14.4 +− 5.9 21.2 +− 5.4 25.0 +− 5.2
Isoleucine a 7.4 +− 1.2 10.4 +− 1.2 12.3 +− 1.9
Leucine a 10.7 +− 1.9 18.5 +− 3.8 24.3 +− 13.3
Lysine 31.8 +− 7.5 29.1 +− 12.1 28.4 +− 6.0
Phenylalanine 9.0 +− 6.3 8.4 +− 3.6 6.5 +− 2.2
Serine a 13.3 +− 3.0 22.3 +− 4.0 25.3 +− 4.5
Threonine b 15.3 +− 2.6 20.4 +− 4.4 22.4 +− 4.5
Tyrosine b 4.4 +− 0.7 6.5 +− 1.5 7.0 +− 1.3
Valine b 6.9 +− 1.0 10.2 +− 2.6 9.4 +− 1.0
Total amino acids b 454 +− 52 582 +− 89 562 +− 62
Glutathione
GSSG 43 +− 7 41 +− 6 47 +− 6
Soluble membrane precursors
2,3-Bisphosphoglycerate 122 +− 40 146 +− 39 183 +− 61
Choline 69 +− 14 70 +− 15 80 +− 38
myo-Inositol c 9.4 +− 6.3 9.7 +− 1.3 15.2 +− 3.4
Phosphocholine 301 +− 85 226 +− 93 253 +− 117
Phosphoethanolamine 52 +− 15 49 +− 20 55 +− 23
Nucleotides and related compounds
ADP 18.0 +− 4.5 15.9 +− 2.5 19.7 +− 8.6
ATP 114 +− 19 111 +− 22 127 +− 22
NAD+ 42 +− 7 35.4 +− 12.7 51 +− 15
NADP+ 4.0 +− 0.7 4.4 +− 1.2 4.5 +− 0.3
Carboxylates
Acetate 10.3 +− 9.0 7.0 +− 3.8 15.6 +− 8.1
Formate 8.6 +− 6.2 9.1 +− 5.5 8.5 +− 4.8
Fumarate 1.0 +− 0.4 0.8 +− 0.5 1.2 +− 0.6
α-Ketoglutarate 2.5 +− 0.7 3.6 +− 1.1 2.6 +− 1.0
Lactate 36.3 +− 14.5 38.5 +− 10.5 43 +− 11
Malate 13.3 +− 8.7 13.7 +− 3.2 10.7 +− 4.5
Succinate a 7.7 +− 1.5 4.0 +− 1.7 3.7 +− 0.5
Other compounds
HEPES c 446 +− 39 479 +− 92 1024 +− 577
Putrescine 14.3 +− 3.6 10.0 +− 5.8 9.4 +− 6.0
Spermidine c 144 +− 29 101 +− 30 87 +− 37
Spermine a 9.9 +− 1.9 22.2 +− 11.6 27.2 +− 9.1
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Table 3 Continued
ANOVA C2GC03 C4Dd2 C67G8
Glucose 6.3 +− 8.5 25.6 +− 31.0 38.7 +− 53.9
Total amounts 1927 +− 227 2005 +− 309 2669 +− 851
Total amounts excluding HEPES 1481 +− 212 1526 +− 255 1646 +− 283
Figure 2 Differences in amino acid amounts in RBCs infected with CQR and CQS parasites
Black bars show the mean amino acid amounts for CQR strains (using averaged data for 7G8, K1, C4Dd2 and C67G8)
divided by those for CQS strains (3D7, D10 and C2GC03). The white bars show the mean amino acid amounts for the
non-transfectant CQR strains (7G8 and K1) divided by those for the non-transfectant CQS strains (3D7 and D10). The grey
bars show the mean amino acid amounts for the transfectant CQR strains (C4Dd2 and C67G8) divided by those for the CQS
transfectant line C2GC03.
either the uptake of [3H]CQ by oocytes expressing PfCRTCQR
or the diffusion of [3H]CQ into non-injected oocytes or oocytes
expressing PfCRTCQS (P>0.05). A modest but significant reduc-
tion in [3H]CQ uptake was observed in PfCRTCQR-expressing oo-
cytes in the presence of 2 mM unlabelled L-aspartate (P<0.05),
whereas the addition of 2 mM unlabelled L-aspartate had no ef-
fect on [3H]CQ uptake into non-injected or PfCRTCQS-expressing
oocytes (P>0.05).
DISCUSSION
Metabolomic comparisons have been applied to great effect in a
variety of systems to unravel physiological differences between
genders, strains, species and healthy versus diseased tissues. In
this study, we have carried out metabolomic comparisons of iR-
BCs, uRBCs and cRBCs, and of RBCs infected with different
strains of P. falciparum.
There were significant differences in the abundance of many
metabolites between iRBCs and uRBCs, with cRBCs having
levels similar to uRBCs for most metabolites (Table 1). As has
been noted previously [34], iRBCs have significantly lower levels
of 2,3-bisphosphoglycerate than their uninfected counterparts.
Glucose was absent from the iRBCs for most of the strains, but
present at significant levels in both uRBCs and cRBCs. This dif-
ference is likely to be due to intracellular glucose in the iRBCs
being consumed by residual glycolysis during the cell isolation
procedure; in the uninfected cells glycolysis is two orders of
magnitude slower [34] and this will not have been an issue. Sor-
bitol was also present at significant levels in uRBCs and cRBCs.
This is consistent with a previous study in which exposure of uR-
BCs to elevated extracellular glucose concentrations was found to
result in an increased intracellular sorbitol content [36]. The end-
product of glycolysis, lactate, was detected in all cell types, but
other glycolytic intermediates were below the level of detection.
As noted previously, the intraerythrocytic parasite has significant
concentrations of TCA cycle intermediates [3,5]. A recent study
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Figure 3 Representative HPLC traces for RBCs infected with C2GC03 (top) or C67G8 (bottom) trophozoites
1. Aspartate, 2. Glutamate, 3. Cystine, 4. Background, 5. Asparagine, 6. Glutamine, 7. Serine, 8. Citrulline, 9. Glycine,
10. 4-Aminobutyrate, 11. Alanine, 12. Threonine, 13. Valine, 14. Derivatization artifact, 15. Methionine, 16. Unknown,
17. Isoleucine, 18. Tryptophan, 19. Phenylalanine, 20. Benzylserine (a non-naturally occurring amino acid to which other
peaks were normalized), 21. Spermine, 22. Ornithine, 23. Lysine, 24. Spermidine.
has provided evidence that a conventional TCA cycle operates at
low levels in asexual blood-stage P. falciparum parasites [37]. Fu-
marate and malate were not detected in either uRBCs or cRBCs.
The detection of succinate in cRBCs, but not uRBCs may be
due to succinate being exported from the parasite and parasitized
RBC, to the external medium (from where it may be taken up by
cRBCs).
The much higher levels of the membrane precursors choline
and phosphocholine in iRBCs than in uRBCs and cRBCs reflects
the fact that the parasite, unlike the mature RBC, carries out
extensive membrane synthesis [38]. The amounts of choline and
phosphocholine differed markedly between iRBCs infected with
different strains, being>30-fold and>5-fold more abundant, re-
spectively, in RBCs infected with 3D7 or 7G8 parasites than in
those infected with D10 or K1 parasites. The basis for this dif-
ference is not known, but may relate to differences in choline
uptake between different parasites. There is physiological evid-
ence for a membrane-potential-dependent choline transporter on
the parasite plasma membrane [39,40] but its molecular iden-
tity (and, therefore, whether there may be polymorphisms in the
transporter in some strains) remains to be discovered.
As has been noted previously, there is a significant concentra-
tion of the neurotransmitter GABA associated with the parasite
[5]. A recent study has reported that TCA cycle intermediates
are used to synthesize glutamate, which is then decarboxylated
to yield GABA in P. falciparum iRBCs [37]. The buffer HEPES,
used widely for malaria parasite culture, is also present (and
highly abundant) in iRBCs infected with all strains. HEPES was
found previously to be an abundant solute in D10 parasites isol-
ated from their host RBCs [5]. The mechanism by which HEPES
gains entry into the parasite is not known; given its physico-
chemical properties, transport proteins are probably involved.
The extent to which the uptake of this exogenous agent might af-
fect the physiology of the parasite is yet to be explored. Previous
mass spectrometry studies have identified additional metabolites
(not detected in this study by 1H-NMR) that differ in abundance
between uRBCs and P. falciparum iRBCs [3,4].
The comparison of the metabolite profiles of RBCs infected
with different CQS and CQR parasites, including parasites ex-
pressing different pfcrt alleles on a single genetic background,
uncovered some significant differences. The most striking find-
ing was that the amounts of many individual amino acids, as well
as the total amount of amino acids, were elevated in RBCs in-
fected with CQR parasites compared to those infected with CQS
parasites. Of particular note was aspartate, which was present in
substantially greater amounts for all (non-transfectant and trans-
fectant) CQR strains (102–185 μmol per 1012 cells) than for all
CQS strains (50–54 μmol per 1012 cells). Asparagine, glycine,
leucine, serine and the polyamine spermine were also found in
greater amounts for all CQR strains than for all CQS strains,
though the relative differences were less pronounced. In the
pfcrt transfectant lines, both the 1H-NMR and HPLC analyses
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Table 4 Relative intracellular metabolite amounts obtained by HPLC in RBCs infected with C2GC03 or C67G8 trophozoites
The data are averaged from three independent cell preparations (obtained on different days) for each line and are shown +− S.E.M. A value >1
indicates that a metabolite is more abundant in C67G8 iRBCs; a value <1 indicates that a metabolite is more abundant in C2GC03 iRBCs. nq, not
quantified because these compounds were not detected in all experiments (asparagine and spermine were only detected in experiments with
C67G8 iRBCs). Red shading: significantly more abundant in C67G8 iRBCs than in C2GC03 iRBCs.
Figure 4 L-Aspartate and CQ uptake by Xenopus oocytes expressing PfCRT
[14C]L-aspartate uptake (a) and [3H]CQ uptake (b) in n.i. (non-injected) oocytes and in oocytes expressing PfCRTCQS,
PfCRTCQR or rat GLAST. Uptake is shown as the means + S.E.M. from nine separate experiments, within which meas-
urements were made from ten oocytes per treatment. (c) Effect of unlabelled L-aspartate (1 and 2 mM) on the uptake
of [3H]CQ into n.i. oocytes (white bars) and oocytes expressing PfCRTCQS (grey bars) or PfCRTCQR (black bars). Uptake is
shown as the means + S.E.M. from three separate experiments, within which measurements were made from ten oocytes
per treatment.
indicated higher glycine and serine levels in parasites bearing
CQ-resistance-conferring mutations in PfCRT, with the relative
differences similar to or greater than that seen for aspartate; how-
ever, the amounts involved were substantially lower than was the
case for aspartate.
The DV is the site at which the parasite digests the haemo-
globin endocytosed from the host RBC. Adult human haemo-
globin contains every proteinogenic amino acid except for
isoleucine, and haemoglobin digestion is essential for parasite
survival [41]. The amino acids produced are used for protein
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synthesis, and the process might also be important to maintain
osmotic balance in the host cell [42] and to ensure that there
is sufficient space for parasite growth inside the RBC [43]. The
extent to which haemoglobin-derived peptides are broken down
within the DV is not yet clear (reviewed in [44]). It is believed
that small peptides, including some dipeptides, are generated
by proteases located in the DV [45]; however, the localization
of exoaminopeptidases that digest small peptides into individual
amino acids has been controversial [46–49]. Based on bioinform-
atic analyses of PfCRT and the requirement that haemoglobin
breakdown products be effluxed from the DV, it has been sug-
gested that the natural function of PfCRT might be amino acid
and/or peptide transport [50].
One potential explanation for our findings was that (wild-type)
PfCRT does indeed transport amino acids out of the DV, and that
this function is compromised in part by CQ-resistance-conferring
mutations, leading to a build-up of amino acids such as aspart-
ate in this organelle. However, neither PfCRTCQS nor PfCRTCQR
mediated aspartate transport when expressed in Xenopus oocytes.
The finding that 2 mM unlabelled L-aspartate caused a modest de-
crease in [3H]CQ uptake by PfCRTCQR-expressing oocytes raises
the possibility of an interaction between aspartate and mutant
PfCRT. However, any such interaction must be low-affinity and
does not result in significant translocation of aspartate.
An alternative possibility is that mutations in PfCRT give rise
to the altered amino acid profile observed here via an indirect
effect. For example, the build-up of amino acids could result from
pfcrt-linked changes in DV physiology that affect haemoglobin
degradation. Indeed, this was suggested in a recent study in which
haemoglobin-derived peptides ranging in size from 2-mers to 32-
mers were shown to accumulate in erythrocytes infected with
CQR parasites [2]. With the exception of GSSG, peptides fell
below the detection limit in our study. Perhaps the small peptides
that are proposed to be trapped within the DV of CQR parasites
[2] degrade over time to produce amino acids, leading to the
increased levels of many amino acids observed in this study.
In summary, a comparison of the metabolite profiles of RBCs
infected with different strains of P. falciparum has revealed sig-
nificant variations between strains, some of which associate with
mutations in PfCRT. The information gained here sheds light on
the biochemical changes brought about by mutations in PfCRT,
and may provide insights into the elusive natural function of this
protein.
AUTHOR CONTRIBUTION
Kiaran Kirk conceived of the study. Rongwei Teng, Adele M. Lehane,
Rowena E. Martin, Pauline R. Junankar and Kiaran Kirk designed
and coordinated the study. Rongwei Teng performed 1H-NMR exper-
iments; Adele M. Lehane and Markus Winterberg performed HPLC
experiments; Sarah H. Shafik and Robert L. Summers performed
Xenopus oocyte experiments; Rongwei Teng, Adele M. Lehane,
Markus Winterberg, Rowena E. Martin and Sarah H. Shafik un-
dertook the analysis of the data. Rongwei Teng, Adele M. Lehane,
Donelly A. van Schalkwyk and Pauline R. Junankar participated
in the preparation of samples for analysis. Adele M. Lehane and
Kiaran Kirk wrote the manuscript, with contributions from all the
authors.
ACKNOWLEDGEMENTS
We are grateful to Professor David Fidock for providing the pfcrt
transfectant lines used in this study, to Professor Stefan Bröer
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